| Risk-taking, locomotor activity and dopamine levels in the nucleus accumbens and medial prefrontal cortex in male rats treated prenatally with alcohol P Muñoz-Villegas, VM Rodríguez, M Giordano, J Juárez Pharmacology Biochemistry and Behavior 153, 88-96, 2017 | 37 | 2017 |
| Neuroadaptive changes and behavioral effects after a sensitization regime of MDPV L Duart-Castells, R López-Arnau, M Buenrostro-Jáuregui, ... Neuropharmacology 144, 271-281, 2019 | 23 | 2019 |
| Changes in CREB and deltaFosB are associated with the behavioural sensitization induced by methylenedioxypyrovalerone M Buenrostro-Jáuregui, A Ciudad-Roberts, J Moreno, P Munoz-Villegas, ... Journal of Psychopharmacology 30 (7), 707-712, 2016 | 18 | 2016 |
| Efficacy and safety of sodium hyaluronate/chondroitin sulfate preservative-free ophthalmic solution in the treatment of dry eye: a clinical trial S Belalcázar-Rey, V Sanchez Huerta, JC Ochoa-Tabares, ... Current Eye Research 46 (7), 919-929, 2021 | 16 | 2021 |
| Assessing impulsivity in prepubertal male rats: A novel device and method to assess motor and cognitive impulsivity. J Juárez, P Muñoz-Villegas, Á Guerrero-Álvarez, P Flores-Ocampo Experimental and clinical psychopharmacology 21 (4), 315, 2013 | 14 | 2013 |
| Comparing the efficacy of an anti-human VEGF-a neutralizing antibody versus bevacizumab on a laser-induced choroidal neovascularization (CNV) rhesus monkey model O Olvera-Montaño, L Baiza-Duran, JD Quintana-Hau, ... Drug Design, Development and Therapy, 3813-3821, 2019 | 12 | 2019 |
| A phase III randomized clinical trial of a 0.5% timolol+ 0.2% brimonidine+ 2.0% dorzolamide fixed combination, preservative-free ophthalmic solution vs. 0.5% timolol+ 0.2 … F Gómez-Aguayo, JA Paczka, R Leñero-Córdova, J Jiménez-Román, ... Ophthalmology and therapy 7, 145-156, 2018 | 11 | 2018 |
| The combination of MDPV and ethanol results in decreased cathinone and increased alcohol levels. Study of such pharmacological interaction R López-Arnau, M Buenrostro-Jáuregui, P Muñoz-Villegas, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 76, 19-28, 2017 | 11 | 2017 |
| Adicción farmacológica y conductual J Juárez, E Barrios De Tomasi, P Muñoz-Villegas, M Buenrostro Cerebro y conducta (González-Garrido A, and Matute E, eds). Guadalajara …, 2013 | 8 | 2013 |
| Pharmacokinetics and safety of an intravitreal humanized anti-VEGF-a monoclonal antibody (PRO-169), a biosimilar candidate to bevacizumab P Muñoz-Villegas, A Sanchez-Rios, MG Quinonez-Alvarado, ... Journal of experimental pharmacology, 545-554, 2021 | 6 | 2021 |
| Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits L Baiza-Durán, A Sánchez-Ríos, J González-Barón, O Olvera-Montaño, ... International Journal of Retina and Vitreous 6, 1-9, 2020 | 6 | 2020 |
| Efficacy and safety of an ophthalmic DMPC-Based nanoemulsion in patients with dry eye disease: a phase I/II randomized clinical Trial LM Baiza-Durán, P Muñoz-Villegas, A Sánchez-Ríos, O Olvera-Montaño Journal of Ophthalmology 2023, 2023 | 3 | 2023 |
| Validation of a preclinical dry eye model in New Zealand white rabbits during and following topical instillation of 1% ophthalmic atropine sulfate A Sánchez‐Ríos, EY Correa‐Gallegos, JM Medina‐Espinoza, ... Animal Models and Experimental Medicine 5 (3), 266-273, 2022 | 3 | 2022 |
| Difluprednate 0.05% versus prednisolone acetate post-phacoemulsification for inflammation and pain: an efficacy and safety clinical trial C Palacio-Pastrana, E Chávez-Mondragón, A Soto-Gómez, ... Clinical Ophthalmology, 1581-1589, 2020 | 3 | 2020 |
| Efficacy and safety of bromfenac 0.09% and sodium hyaluronate 0.4% combination therapy, versus placebo in patients with pterygium I–III for clinical signs on ocular inflammation E Chávez-Mondragón, C Palacio, A Soto-Gómez, M Villanueva-Nájera, ... Clinical Ophthalmology, 781-787, 2019 | 3 | 2019 |
| Evaluation of the Relationship Between Diabetic Macular Edema and Renal Function in a Latino Population JM Torres-Arellano, A Tornero-Jimenez, A Sánchez-Ríos, ... Ophthalmology and Therapy 12 (5), 2745-2755, 2023 | 1 | 2023 |
| Efficacy and safety of Bromfenac 0.09% ophthalmic solution in reducing clinical inflammation and symptoms relief in patients with pterygium I-III OO Montaño, LM Baiza-Duran, P del Carmen Muñoz-Villegas, FG Velez, ... Investigative Ophthalmology & Visual Science 60 (9), 4725-4725, 2019 | 1 | 2019 |
| phase III, randomized, clinical, crossover study to evaluate the non-inferiority of an ophthalmic solution of preservative-free latanoprost at 0.005% in patients with primary … VE Sánchez-Castellanos, JA Paczka, F Gómez-Aguayo, F Gil-Carrasco, ... New Front Ophthalmol 4, 1-7, 2018 | 1 | 2018 |
| The Effect of Sodium Hyaluronate Eye Drops 2, 4 or 6 Times a Day on Signs and Symptoms of Dry Eye Disease PC Muñoz-Villegas, A Sánchez-Ríos, O Olvera-Montaño Clinical Ophthalmology, 2945-2955, 2023 | | 2023 |
| Determinants of adherence to treatment in patients with ophthalmic conditions P Muñoz-Villegas, H Martínez-Bautista, O Olvera-Montaño Expert Review of Clinical Pharmacology 16 (12), 1249-1259, 2023 | | 2023 |
David PubillUniversitat de Barcelona. Dept. de Farmacologia, Toxicologia i Química TerapèuticaDirección de correo verificada de ub.edu
